Skip to main content
HLB PHARMACEUTICAL CO., LTD. logo

HLB PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 047920 ISIN · KR7047920004 KO Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2024-03-15 Director's Dealing
Country KR South Korea
Listing KO 047920

About HLB PHARMACEUTICAL CO., LTD.

https://www.hlbpharma.co.kr/eng/

HLB PHARMACEUTICAL CO., LTD. is a biopharmaceutical company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company specializes in the production of quasi-drugs, such as alcohol swabs for disinfecting wounds and sterilizing medical devices. Its portfolio also includes prescription medications like skeletal muscle relaxants. A key focus of its research and development activities is the discovery and advancement of new peptide-based drugs. As part of the broader HLB Group, it contributes to a diverse portfolio that spans pharmaceuticals, medical devices, and diagnostics.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details a change in share ownership by an executive (Lim Chul An) of HLB Pharma. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2024-03-15 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted by HLB Pharmaceutical regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date where many companies hold their AGMs). It explains the reason for choosing this date and acknowledges the company's participation status in the voluntary compliance program for AGM dispersion. Since this is a regulatory notification regarding meeting logistics rather than the meeting materials themselves, the proxy statement, or the results, it falls under the general regulatory filing category.
2024-03-12 Korean
주주총회소집결의 (정기주주총회)
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by HLB Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits) for the upcoming Annual General Meeting. This document serves as the official solicitation and notification for shareholders to attend or vote, which falls under the Proxy Solicitation & Information Statement category.
2024-03-12 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (HLB Pharmaceutical) regarding a correction to a previously filed report on financial performance (specifically, a change in revenue or profit/loss structure). It details the specific line items that were adjusted due to the audit process. This type of filing is a standard regulatory disclosure in the Korean market (DART system) for material financial changes, which falls under the 'Regulatory Filings' category as it is a specific corporate disclosure that does not fit into the other specialized categories like 10-K or Earnings Release. FY 2023
2024-03-12 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Solicitation of Proxy Statement) for HLB Pharmaceutical Co., Ltd. It contains information regarding the upcoming Annual General Meeting (AGM), including the agenda items (approval of financial statements, appointment of directors/auditors, and remuneration limits), proxy solicitation details, and voting procedures. This document is a standard proxy solicitation material sent to shareholders to request their votes for the meeting.
2024-03-12 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for HLB Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors and auditors, and remuneration limits. This document is a formal proxy statement sent to shareholders to provide information and request votes for the meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2024-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.